Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 11—November 2019
Research Letter

Availability of Injectable Antimicrobial Drugs for Gonorrhea and Syphilis, United States, 2016

William S. PearsonComments to Author , Donald K. Cherry, Jami S. Leichliter, Laura H. Bachmann, Nicole A. Cummings, and Matthew Hogben
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (W.S. Pearson, J.S. Leichliter, L.H. Bachmann, M. Hogben); Centers for Disease Control and Prevention, Hyattsville, Maryland, USA (D.K. Cherry, N.A. Cummings)

Main Article

Table

On-site availability of drugs to manage gonorrhea and syphilis and likelihood of drug nonavailability by type and location of clinic, United States, 2016*

Category Weighted population, no. (95% CI) On-site drug availability, % (95% CI)
Likelihood of nonavailability†
Yes No β OR (95% CI)
Ceftriaxone, 250 mg, intramuscular
PCMH designation‡
Yes 44,028 (35,296–52,760) 54.4 (42.1–66.3) 45.6 (33.7–57.9) Referent Referent
No 89,381 (79,356–99,406) 37.3 (30.0–45.0) 62.7 (55.0–70.0) 0.71 2.03 (1.15–3.57)
Region of office§
Northeast 33,384 (28,666–38,102) 34.3 (22.7–47.5) 65.7 (52.5–77.3) Referent Referent
South 45,574 (39,694–51,454) 49.0 (38.4–59.6) 51.0 (40.4–61.6) −0.63 0.53 (0.27–1.06)
Midwest 33,296 (28,374–38,218) 41.4 (28.9–54.8) 58.6 (45.2–71.1) −0.28 0.76 (0.35–1.64)
West
37,228 (31,038–43,418)
48.6 (35.8–61.6)
51.4 (38.4–64.2)

−0.62
0.54 (0.26–1.14)
Penicillin G benzathine, 2.5 million units, intramuscular
PCMH designation‡
Yes 44,028 (35,296–52,760 34.2 (23.2–46.6) 65.8 (53.4–76.8) Referent Referent
No 89,381 (79,356–99,406) 14.6 (9.5–21.1) 85.4 (78.9–90.5) 1.16 3.20 (1.63–6.29)
Region of office§
Northeast 33,384 (28,666–38,102) 17.8 (8.9–30.3) 82.2 (69.7–91.1) Referent Referent
South 45,574 (39,694–51,454) 32.1 (22.8–42.5) 67.9 (57.5–77.2) −0.83 0.43 (0.19–1.00)
Midwest 33,296 (28,374–38,218) 15.5 (7.3–27.3) 84.5 (72.7–92.7) 0.22 1.25 (0.46–3.39)
West 37,228 (31,038–43,418) 19.6 (9.4–33.8) 80.4 (66.2–90.6) −0.13 0.88 (0.32–2.40)

*The data source was the National Center for Health Statistics, National Ambulatory Medical Care Survey (5). All analyses were conducted by using SUDAAN (https://www.rti.org/impact/sudaan-statistical-software-analyzing-correlated-data) to account for the complex sampling design of the survey. OR, odds ratio; PCMH, patient-centered medical home.
†Likelihood determined by using a logistic regression model that included the factors PCMH designation and region of country. β is the coefficient of the variable, indicating direction and strength of the association.
‡PCMH designation of first-listed National Ambulatory Medical Care Survey–sampled office. An estimated weighted total of 149,483 office-based physicians indicated that they evaluate patients for or treat patients with sexually transmitted infections at their first-listed sampled office. PCMH data were missing (i.e., the physician refused to answer, did not know, or left blank or an instrument error occurred) for 10.8% of weighted office-based physicians treating gonorrhea and syphilis.
§Estimates might not sum to the estimated weighted total because of rounding of weighted numbers.

Main Article

References
  1. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2017. Atlanta: US Department of Health and Human Services; 2018.
  2. Kirkcaldy  RD, Bolan  GA, Wasserheit  JN. Cephalosporin-resistant gonorrhea in North America. JAMA. 2013;309:1857. DOIPubMedGoogle Scholar
  3. Nurse-Findlay  S, Taylor  MM, Savage  M, Mello  MB, Saliyou  S, Lavayen  M, et al. Shortages of benzathine penicillin for prevention of mother-to-child transmission of syphilis: An evaluation from multi-country surveys and stakeholder interviews. PLoS Med. 2017;14:e1002473. DOIPubMedGoogle Scholar
  4. Workowski  KA, Bolan  GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(No. RR-3):1137.PubMedGoogle Scholar
  5. Centers for Disease Control and Prevention National Center for Health Statistics. Ambulatory health care data. 2019 Jul 3 [cited 2019 May 29]. https://www.cdc.gov/nchs/ahcd/index.htm
  6. American Medical Association. Principles of the patient-centered medical home H-160.919. 2018 [cited 2019 May 29]. https://policysearch.ama-assn.org/policyfinder/detail/Principles%20of%20the%20Patient-Centered%20Medical%20Home%20H-160.919?uri=%2FAMADoc%2FHOD.xml-0-734.xml
  7. McHugh  M, Shi  Y, Ramsay  PP, Harvey  JB, Casalino  LP, Shortell  SM, et al. Patient-centered medical home adoption: results from aligning forces for quality. Health Aff (Millwood). 2016;35:1419. DOIPubMedGoogle Scholar

Main Article

Page created: October 16, 2019
Page updated: October 16, 2019
Page reviewed: October 16, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external